[HTML][HTML] Perioperative durvalumab for resectable non–small-cell lung cancer
Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …
[HTML][HTML] Novel targets for immune-checkpoint inhibition in cancer
Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …
[HTML][HTML] Immunotherapy-based combinations in metastatic NSCLC
Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer
(mNSCLC) since the approval of immunotherapy by the US FDA in 2015. Despite the …
(mNSCLC) since the approval of immunotherapy by the US FDA in 2015. Despite the …
IL6 mediates suppression of T-and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Purpose: Patients with advanced non–small cell lung cancer (NSCLC) harboring activating
EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However …
EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However …
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
D Miao, J Zhao, Y Han, J Zhou, X Li… - Cancer …, 2024 - Wiley Online Library
Lung cancer is the second most common and the deadliest type of cancer worldwide.
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …
Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of …
Perioperative systemic therapy for resectable non–small cell lung cancer
Despite remarkable treatment advancements in patients with advanced non–small cell lung
cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains …
cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains …
Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer: A Review
Importance Although cancer-related mortality continues to decline, lung cancer remains the
No. 1 cause of cancer deaths in the US. Almost half of the patients with non–small cell lung …
No. 1 cause of cancer deaths in the US. Almost half of the patients with non–small cell lung …
Lung cancer immunotherapy: Beyond common immune checkpoints inhibitors
M Catalano, S Shabani, J Venturini, C Ottanelli… - Cancers, 2022 - mdpi.com
Simple Summary The lung cancer treatment paradigm has been completely changed by
immunotherapy; however, less than half of the treated patients obtain a response, and an …
immunotherapy; however, less than half of the treated patients obtain a response, and an …
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Only a minority of lung cancers are resectable at diagnosis, and many of these will
eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage …
eventually relapse. Adjuvant chemotherapy in this setting has a modest survival advantage …
New immuno-oncology targets and resistance mechanisms
MC Tokaz, CS Baik, AMG Houghton… - Current Treatment Options …, 2022 - Springer
Opinion statement Immune checkpoint inhibition (ICI) has revolutionized the field of non-
small cell lung cancer (NSCLC); currently, most patients with advanced disease receive …
small cell lung cancer (NSCLC); currently, most patients with advanced disease receive …